Coherus BioSciences (CHRS +16.7%) inks a deal with Singapore-based Temasek for the private placement of $150M in …
Coherus has agreed to file a registration statement covering the resale of the shares of common stock acquired by the investors ... late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 …
"Maybe (Chen) would push to sell Fort Wayne," he said. Beyond divestitures, there's little Chen or other board members can advise from an operating standpoint to get CHS's stock moving upward, Tanquilut said. The company is recruiting …
The second tranche is projected to be funded following receipt of the U.S. Food and Drug Administration’s marketing approval for the CHS-1701 pegfilgrastim biosimilar product candidate, subject to market pricing and certain closing …
with 6,556,116 shares of common stock to be issued at an offering price of $11.44 per share. The second tranche is projected to be funded following receipt of the U.S. Food and Drug Administration’s (FDA) marketing approval for the …
Tianqiao Chen’s Shanda group of companies disclosed its latest buying spree Tuesday morning and said it has now invested nearly $257 million in CHS, which has struggled with high debt and the integration of Health Management …
But making Chico's FAS Inc an even more interesting and timely stock to look at, is the fact that in trading on Tuesday, shares of CHS entered into oversold territory, changing hands as low as $7.77 per share. We define oversold territory …
Shares of Chico'S Fas Inc (NYSE:CHS) traded today at $7.80 ... on a current price of $7.89 and an average consensus analyst price target of $11.83. The stock should run into initial resistance at its 50-day moving average (MA) of $12.70 …
Shares of Chico\'s FAS Inc. (CHS) sank into a new 52-week low yesterday, and could be a company to watch at the open. The company’s stock fell to as low as $8.35 yesterday after opening at $8.90. By the closing bell, the company's stock
2017 with 6.6 million shares of common stock * Coherus Biosciences Inc - ‍Second tranche is projected to be funded following receipt of U.S. FDA marketing approval for CHS-1701 * Coherus Biosciences - Intends to use net proceeds …